[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622392":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":20,"armGroups":21,"interventions":27,"overallOfficials":33,"centralContacts":37,"locations":45,"responsibleParty":58,"collaborators":11,"id":60,"slug":11,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":11,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":11,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Incidence of adverse events (AEs) and\u002For serious AEs (SAEs)",null,"Up to 52 weeks",{"measure":14,"description":11,"timeFrame":12},"Actions taken after adverse events (AEs) and\u002For serious AEs (SAEs)",{"measure":16,"description":11,"timeFrame":12},"Outcome of adverse events (AEs) and\u002For serious AEs (SAEs)",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":18,"timePerspective":19,"maskingInfo":11},"COHORT","PROSPECTIVE","The study population will consist of adults diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiate mavacamten treatment at medical institutions in Japan",[22],{"label":23,"type":11,"description":24,"interventionNames":25},"Cohort 1","Participants with obstructive hypertrophic cardiomyopathy receiving mavacamten treatment",[26],"Drug: Mavacamten",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","Mavacamten","According to the product label",[23],[34],{"name":35,"affiliation":5,"role":36},"Bristol Myers Squibb","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":44,"role":40,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[46],{"facility":47,"status":48,"city":49,"state":11,"zip":11,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":11},"CMIC Co., Ltd","RECRUITING","Tokyo","Japan","JP",{"type":53,"coordinates":54},"Point",[55,56],139.69171,35.6895,{"lat":56,"lon":55},{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100622392",false,"NCT07383025","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan","Inclusion Criteria:\n\n• All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study\n\nExclusion Criteria:\n\n• Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study","ALL","18 Years",{"count":69,"type":70},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan",[74],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[76],"Obstructive hypertrophic cardiomyopathy (oHCM)","2026-01-26",{"date":79,"type":80},"2026-02-03","ACTUAL",{"date":82,"type":80},"2025-05-21",{"date":84,"type":70},"2029-11-30",{"name":5,"class":6},1]